Sponsored by: Advenchen Laboratories, LLC.
Anlotinib (AL3818), a tyrosine kinase inhibitor, is an investigational drug being evaluated in the treatment of Alveolar Soft Part Sarcoma and other sarcomas. Anlotinib was studied in soft tissue sarcomas in a phase 2 trial and demonstrated encouraging results in Alveolar Soft Part Sarcoma. The results were presented at the ASCO 2016 annual meeting. The promising phase 2 results paved the way for APROMISS, the phase 3 study, which is currently open to recruitment in the United States with plans to open globally in Japan and Europe.
The objective of APROMISS is to assess the effectiveness and safety of Anlotinib in subjects with metastatic or advanced Alveolar Soft Part Sarcoma and other sarcomas. The FDA also granted orphan drug designation to Anlotinib for the the potential treatment of soft tissue sarcoma, designation which is granted for drugs intended for diseases or conditions that affect fewer than 200,000 people in the United States.
Eligibility: Individuals 18 years of age and older with locally advanced or metastatic Alveolar Soft Part Sarcoma who are not candidates for surgical resection. Please note that other eligibility criteria do apply – for further details please go to the ClinicalTrials.gov page at https://clinicaltrials.gov/ ct2/show/NCT03016819.
Melissa Chen at: email@example.com
Judy Chen at: firstname.lastname@example.org
Locations: Miami, FL; Ann Arbor, Michigan; Los Angeles, CA; Stanford, CA
Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)